{"organizations": [], "uuid": "08e4ae9ae86047ae30d71056dbd7f6416d636dc5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ovid-therapeutics-announces-ov101/brief-ovid-therapeutics-announces-ov101-granted-fast-track-designation-by-fda-for-fragile-x-syndrome-treatment-idUSASC09SEZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome Treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-15T14:23:00.000+02:00", "replies_count": 0, "uuid": "08e4ae9ae86047ae30d71056dbd7f6416d636dc5"}, "author": "", "url": "https://www.reuters.com/article/brief-ovid-therapeutics-announces-ov101/brief-ovid-therapeutics-announces-ov101-granted-fast-track-designation-by-fda-for-fragile-x-syndrome-treatment-idUSASC09SEZ", "ord_in_thread": 0, "title": "BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome Treatment", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "min read   ovid therapeutics inc", "sentiment": "none"}, {"name": "fda for fragile x syndrome treatment reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 25 PM / Updated 20 minutes ago BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome Treatment Reuters Staff 1 Min Read   Ovid Therapeutics Inc: * OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF FRAGILE X SYNDROME * OVID THERAPEUTICS INC - ‍INTENDS TO INITIATE A PHASE 2 CLINICAL TRIAL IN 2018​ * OVID - ‍TOPLINE DATA FROM PHASE 2 STARS CLINICAL TRIAL INVESTIGATING OV101 EXPECTED IN SECOND HALF OF 2018​ Source text for Eikon:  ", "external_links": [], "published": "2018-03-15T14:23:00.000+02:00", "crawled": "2018-03-15T14:42:19.114+02:00", "highlightTitle": ""}